| Cytokine release syndrome in severe COVID-19 #MMPMID32303591Moore JB; June CHScience 2020[May]; 368 (6490): 473-474 PMID32303591show ga
ä|Antibodies, Monoclonal, Humanized/therapeutic use[MESH]|Betacoronavirus[MESH]|C-Reactive Protein/analysis[MESH]|COVID-19[MESH]|Coronavirus Infections/*pathology[MESH]|Cytokine Release Syndrome/*etiology[MESH]|Humans[MESH]|Immunotherapy, Adoptive[MESH]|Interleukin-6/antagonists & inhibitors/blood[MESH]|Lymphohistiocytosis, Hemophagocytic/etiology[MESH]|Pandemics[MESH]|Pneumonia, Viral/*pathology[MESH]|Receptors, Chimeric Antigen[MESH]|Respiratory Distress Syndrome/etiology[MESH]|SARS-CoV-2[MESH]
DeepDyve Pubget Overpricing |
|